Skip to main content
TipRanks
Go Ultimate75% OFF

SK Biopharmaceuticals Co., Ltd. (326030) Stock Statistics & Valuation Metrics

Total Valuation

SK Biopharmaceuticals Co., Ltd. has a market cap or net worth of KRW 6.97T. The enterprise value is KRW 5.40T.

Market Cap
KRW 6.97T
Enterprise Value
KRW 5.40T

Share Statistics

SK Biopharmaceuticals Co., Ltd. has 78,313,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
78,313,250
Owned by Insiders
―
Owned by Institutions
4.65%

Financial Efficiency

SK Biopharmaceuticals Co., Ltd.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is 22.17%.

Return on Equity (ROE)
0.33
Return on Assets (ROA)
0.22
Return on Invested Capital (ROIC)
22.17%
Return on Capital Employed (ROCE)
0.23
Revenue Per Employee
2.93B
Profits Per Employee
1.11B
Employee Count
241
Asset Turnover
0.59
Inventory Turnover
0.55

Valuation Ratios

The current PE Ratio of SK Biopharmaceuticals Co., Ltd. is 18.31. SK Biopharmaceuticals Co., Ltd.’s PEG ratio is 1.24.

PE Ratio
18.31
PS Ratio
7.25
PB Ratio
6.43
Price to FCF
24.63
Price to Operating Cash Flow
23.92
PEG Ratio
1.24

Income Statement

In the last 12 months, SK Biopharmaceuticals Co., Ltd. had revenue of 706.74B and earned 266.95B in profits. Earnings per share was 3408.75.

Revenue
706.74B
Gross Profit
651.67B
Operating Income
203.94B
Pretax Income
150.88B
Net Income
266.95B
EBITDA
220.89B
Earnings Per Share (EPS)
3408.75

Cash Flow

In the last 12 months, operating cash flow was 251.61B and capital expenditures -7.82B, giving a free cash flow of 243.78B billion.

Operating Cash Flow
251.61B
Free Cash Flow
243.78B
Free Cash Flow per Share
3487.80

Dividends & Yields

SK Biopharmaceuticals Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
4.06%
Earnings Yield
5.67%

Stock Price Statistics

Beta
0.14
52-Week Price Change
-32.26%
50-Day Moving Average
78228.00
200-Day Moving Average
89783.50
Relative Strength Index (RSI)
68.12
Average Volume (3m)
159.34K

Important Dates

SK Biopharmaceuticals Co., Ltd. upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 16, 2026
Next Earnings Date
Feb 10, 2027
Ex-Dividend Date
―

Financial Position

SK Biopharmaceuticals Co., Ltd. as a current ratio of 2.31, with Debt / Equity ratio of 6.02%

Current Ratio
2.31
Quick Ratio
1.97
Debt to Market Cap
0.00
Net Debt to EBITDA
-1.17
Interest Coverage Ratio
26.52

Taxes

In the past 12 months, SK Biopharmaceuticals Co., Ltd. has paid -102.37B in taxes.

Income Tax
-102.37B
Effective Tax Rate
-0.68

Enterprise Valuation

SK Biopharmaceuticals Co., Ltd. EV to EBITDA ratio is 22.25, with an EV/FCF ratio of 23.17.

EV to Sales
6.82
EV to EBITDA
22.25
EV to Free Cash Flow
23.17
EV to Operating Cash Flow
22.51

Balance Sheet

SK Biopharmaceuticals Co., Ltd. has KRW 381.87B in cash and marketable securities with KRW 48.83B in debt, giving a net cash position of KRW 333.05B billion.

Cash & Marketable Securities
KRW 381.87B
Total Debt
KRW 48.83B
Net Cash
KRW 333.05B
Net Cash Per Share
KRW 4,252.74
Tangible Book Value Per Share
KRW 12.34K

Margins

Gross margin is 92.32%, with operating margin of 37.65%, and net profit margin of 41.07%.

Gross Margin
92.32%
Operating Margin
37.65%
Pretax Margin
34.75%
Net Profit Margin
41.07%
EBITDA Margin
31.06%
EBIT Margin
29.37%

Analyst Forecast

The average price target for SK Biopharmaceuticals Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
37.40%
EPS Growth Forecast
18.94%

Scores

Smart Score
―
AI Score
69